Cellectar Biosciences has a 1 year low of $1.25 and a 1 year high of $7.85.

Source: https://www.dailypolitical.com/2023/04/08/stocknews-com-begins-coverage-on-cellectar-biosciences-nasdaqclrb.html

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer.

Source: https://www.dailypolitical.com/2023/01/11/cellectar-biosciences-nasdaqclrb-now-covered-by-stocknews-com.html

Citadel Advisors LLC acquired a new stake in shares of Cellectar Biosciences in the second quarter worth approximately $60,000.

Source: https://www.americanbankingnews.com/2023/09/14/cellectar-biosciences-nasdaqclrb-coverage-initiated-by-analysts-at-stocknews-com.html